GH RESEARCH PLC
NASDAQ: GHRS (GH Research PLC)
Last update: 12 hours ago12.72
0.53 (4.35%)
| Previous Close | 12.19 |
| Open | 12.16 |
| Volume | 543,297 |
| Avg. Volume (3M) | 176,759 |
| Market Cap | 789,014,016 |
| Price / Book | 2.45 |
| 52 Weeks Range | |
| Earnings Date | 9 Sep 2025 |
| Diluted EPS (TTM) | -0.790 |
| Total Debt/Equity (MRQ) | 0.21% |
| Current Ratio (MRQ) | 29.71 |
| Operating Cash Flow (TTM) | -41.26 M |
| Levered Free Cash Flow (TTM) | -27.93 M |
| Return on Assets (TTM) | -11.97% |
| Return on Equity (TTM) | -16.20% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | GH Research PLC | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 0.5 |
| Average | 0.63 |
|
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 33.88% |
| % Held by Institutions | 68.88% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bvf Inc/Il | 31 Mar 2025 | 8,827,712 |
| Lynx1 Capital Management Lp | 31 Mar 2025 | 6,443,940 |
| Rtw Investments, Lp | 31 Mar 2025 | 5,499,769 |
| Cormorant Asset Management, Lp | 31 Mar 2025 | 2,009,482 |
| Deep Track Capital, Lp | 31 Mar 2025 | 2,000,000 |
| Toronto Dominion Bank | 31 Mar 2025 | 1,967,293 |
| Deerfield Management Company, L.P. (Series C) | 31 Mar 2025 | 925,000 |
| Jefferies Financial Group Inc. | 31 Mar 2025 | 750,000 |
| 5Am Venture Management, Llc | 31 Mar 2025 | 572,665 |
| Alyeska Investment Group, L.P. | 31 Mar 2025 | 454,975 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 214.47%) | Buy |
| Median | 39.00 (206.60%) | |
| Low | 29.00 (Guggenheim, 127.99%) | Buy |
| Average | 36.00 (183.02%) | |
| Total | 3 Buy | |
| Avg. Price @ Call | 11.10 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| JMP Securities | 24 Jun 2025 | 39.00 (206.60%) | Buy | 12.54 |
| Guggenheim | 09 May 2025 | 29.00 (127.99%) | Buy | 10.38 |
| HC Wainwright & Co. | 09 May 2025 | 40.00 (214.47%) | Buy | 10.38 |
| Date | Type | Details |
|---|---|---|
| 20 Jun 2025 | Announcement | GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule |
| 15 May 2025 | Announcement | GH Research Announces Acceptance of Pharmaceutical Pipeline Presentation and Late-Breaking Posters at the American Society of Clinical Psychopharmacology 2025 Annual Meeting |
| 08 May 2025 | Announcement | GH Research Reports First Quarter 2025 Financial Results and Provides Business Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |